Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.

[1]  Yup Kang,et al.  Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways , 2021, Journal of immunology research.

[2]  W. Ogawa,et al.  Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. , 2021, Biochemical and biophysical research communications.

[3]  S. Kaneko,et al.  LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH , 2021, Scientific reports.

[4]  Janice H. Jou,et al.  Nonalcoholic Fatty Liver Disease and Recent Guideline Updates , 2021, Clinical liver disease.

[5]  S. Wen,et al.  Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis , 2020, Frontiers in Immunology.

[6]  M. Helal,et al.  Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver. , 2020, International immunopharmacology.

[7]  F. Negro.  Natural history of NASH and HCC , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[8]  M. Ishigami,et al.  Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects , 2020, Scientific Reports.

[9]  X. Ouyang,et al.  The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. , 2019, Annals of translational medicine.

[10]  Wei Wang,et al.  Canagliflozin exerts anti‐inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells , 2018, Biochemical pharmacology.

[11]  B. Fuchs,et al.  Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis , 2018, Scientific Reports.

[12]  K. Atabai,et al.  Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1‐mediated regulation of superoxide , 2017, Free radical biology & medicine.

[13]  N. Arsenijević,et al.  Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis , 2016, World journal of gastroenterology.

[14]  Jun Yu,et al.  C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication , 2016, Expert Reviews in Molecular Medicine.

[15]  M. Blüher,et al.  The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. , 2016, Metabolism: clinical and experimental.

[16]  H. J. Yoo,et al.  A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression. , 2015, Biochemical pharmacology.

[17]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[18]  T. Asano,et al.  DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. , 2015, American journal of physiology. Endocrinology and metabolism.

[19]  M. Cho,et al.  Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. , 2014, European journal of pharmacology.

[20]  A. Tahrani,et al.  SGLT inhibitors in management of diabetes. , 2013, The lancet. Diabetes & endocrinology.

[21]  G. Yılmaz,et al.  Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. , 2013, Metabolic syndrome and related disorders.

[22]  L. Gan,et al.  NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications , 2012, Gut and liver.

[23]  Y. Terauchi,et al.  Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice , 2011, Diabetes.

[24]  S. French,et al.  Oxidative stress and regulation of anti‐oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non‐alcoholic fatty liver , 2010, Journal of gastroenterology and hepatology.

[25]  P. Newsome,et al.  Pathogenesis of non-alcoholic fatty liver disease , 2009, QJM : monthly journal of the Association of Physicians.

[26]  B. Okopień,et al.  Inhibitors of type 2 sodium glucose co-transporters — a new strategy for diabetes treatment , 2009, Pharmacological reports : PR.

[27]  N. Thornberry,et al.  Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). , 2009, Best practice & research. Clinical endocrinology & metabolism.

[28]  J. Iredale,et al.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.